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Renal Denervation Using an
Irrigated Radiofrequency
Ablation Catheter for
Management of
Drug-Resistant Hypertension
A Demonstrated Value?*
Edward D. Frohlich, MD
New Orleans, Louisiana
Ahmed et al. (1) clearly define the 3-fold purpose of their
paper: 1) new therapeutic approach for renal denervation;
2) description of their irrigated radiofrequency ablation
catheter technique; and 3) the indication for the use of this
procedure (i.e., management of drug-resistant hyperten-
sion). Each of these highlighted points are worthy of
editorial discussion.
See page 758
Importance. First and foremost is the clinical problem for
hich this newly advanced technique has been designed:
rug-resistant hypertension. The magnitude of this problem
ay be overinterpreted. There are over 60 million potential
atients with hypertension in the United States and far
ore when one considers that 100% of very old individuals
i.e., 80 years of age) also have hypertension. Therefore,
he fundamental clinical problem is not that of “drug
esistance” but hypertension resistant to multidrug therapy,
hich occurs in only a minority of patients with hyperten-
ion. Most assuredly, by far, over 60% of these potential
atients with hypertension either remain unrecognized or
re untreated or have been entered into a treatment program
ut do not have their blood pressures controlled (2). Only a
mall fraction of patients with hypertension actually have
drug-resistant hypertension.” Many of these patients may
dhere poorly to the prescribed treatment (3).
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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re to control blood pressure (140 mm Hg systolic and
90 mm Hg diastolic) relates to inappropriate selection of
edications, inadequate medical follow-up, or that the
atient has not been advised about his/her treatment pro-
ram, which includes nondrug therapeutic approaches that
ay not have been clearly promoted. These latter lifestyle
echanisms may not have been provided if the doctor/
atients relationship is simply “touching third base on the
ay home.” Therefore, first and foremost, the patient must
nderstand fully his/her overall treatment program. In this
egard, a realistic dietary control program is necessary and
ust also include a clear-cut understanding concerning the
ecessity for controlling the sodium content of the patient’s
iet (4). In addition, a meaningful weight control regimen
ith alcohol moderation must always be emphasized
2,5,6). This latter consideration is particularly applicable to
he elderly population whose alcohol intake frequently may
e unappreciated and unrecognized.
The next important issue is that of a very specific
efinition of “drug-resistant” hypertension. The patient
ith drug-resistant hypertension must be receiving at least 3
ifferent antihypertensive drugs, including a diuretic (2,7,8).
he purpose of the diuretic must be appreciated by the
rescribing healthcare provider. It includes the realization
hat blood pressure reduction with antihypertensive drugs
ay be frequently associated with intravascular volume fluid
xpansion, and the necessary addition of a diuretic (with
areful attention to potassium balance) may very well
nhance the antihypertensive effectiveness. Further, remem-
er that all potassium-retaining agents are not diuretics.
ach of these foregoing concerns have been well docu-
ented over the years, from the original publications
receding the Joint National Committee’s 7 reports,
hrough specific reports and the many supplements that
etail nondrug treatment issues as well as the specific drug
ctions (2,6,8,9).
Patient selection. Having defined the underlying problem
and definition of the drug-resistant state, the major issue
remains proper selection of the patient for catheter inter-
vention by renal denervation treatment. This selection
begins in the physician’s office. Is the provider certain that
the patient is receiving the appropriate number and types of
prescribed pharmacological agents and that the patient’s
blood pressure (not the drugs) is actually “drug resistant.”
To my way of thinking, this should be demonstrated, if
possible, on a repeated office visit, during which time, the
overall adherence to treatment is confirmed and that both
the patient and physician are truly aware of the importance
and inclusion of prescribed nondrug treatment modalities.
Renal sympathetic innervation and denervation. A clear
understanding of the physiological importance of renal
innervation has been well documented over the years (10–15).
The medical literature has emphasized repeatedly the im-
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767portance of the renin-angiotensin-aldosterone system in
maintaining control of blood pressure and the pathophysi-
ological importance of this system in participation in various
aspects of hypertensive disease and treatment. Further
discussion of this issue is not necessary for the purview of
this editorial. However, recognition of the value of other
invasive surgical approaches (i.e., thoracodorsal sympathec-
tomy) and pharmacological agents (including antiadrenergic
compounds) in the publications concerning treatment of
hypertension is also abundantly available. Thus, a number of
reports are available for reference dealing with the impor-
tance of the adrenergic nervous system for the role of renal
innervation and denervation in maintaining renal function
and blood pressure control (2,10–17). Thus, the literature is
replete with justification of the merits, indications, and
potential value of renal denervation procedures (2).
Catheter approach to denervation. Recently, several publi-
cations have appeared introducing a new technique of a
catheter-based renal denervation for patients with drug-
resistant hypertension (18–20). These reports have provided
the need for selecting patients for renal denervation and the
selection process involving a meaningful number of patients
with drug-resistant hypertension who may be subjected to
the procedure of catheter-based renal denervation. Indeed,
the procedure, indications, and its value have attracted the
attention of, perhaps, an overexcited lay press as well as
physicians and concerned patients.
Renal denervation with a saline-irrigated radiofrequency
ablation catheter. The use of catheter-based techniques for
procedures involving a catheter means for denervation is not
new to intervention-oriented cardiovascular physicians.
This therapeutic procedure has been employed by electro-
physiological cardiologists for ablation of cardiac and great
vessel centers and has been shown to be of value in patients
with cardiac dysrhythmias safely and with efficacy for some
time.
Although found to be of value and of success in a
substantial number of patients with drug-resistant hyperten-
sion, the value of saline-irrigated catheters has been said to
have putative advantages for preventing thrombus formation at
the ablation catheter site (1). The merits and details of this
catheter for bilateral renal sympathetic nerve denervation is
discussed in technical detail by Ahmed et al. (1) elsewhere in
this issue of JACC: Cardiovascular Interventions. However, as
suggested by these authors, the new and current experimental
technique employed by the Symplicity HTN (Renal Sympa-
thetic Denervation in Patients With Treatment-Resistant
Hypertension) trials involves a solid-tip radiofrequency abla-
tion catheter which Ahmed et al. (1) indicate may promote
thrombus/char formation at the catheter sites along the renal
artery. This potential complication has not been reported in the
number of patients reported from 19 centers from Australia,
Europe, and the United States (18–22). Although renal
arterial dissection was reported in 1 patient, and a few othervascular complications were reported before the ablation pro-
cedure, none were said to be related to catheter-induced
ablation in the Symplicity study (18–22). Thus, there appears
to be no patients who developed thrombosis/char, although
reference was made to this potential by Ahmed et al. (1). Their
saline-irrigated catheter was used by the authors in (only) 10
essential hypertensive patients from the Homolka Hospital,
Prague, Czech Republic, who were shown to have drug-
resistant hypertension and were without evidence of renal
arterial disease or other secondary forms of hypertension,
impaired glomerular filtration rate 45 ml/min, diabetes,
previous stenting, or angioplasty. A detailed description of the
procedure using the saline-irrigated catheter was provided, and
the averaged arterial pressure reduction of their study was
compared with that experienced in the Symplicity trial. How-
ever, comparison of these 2 reports do not permit a valid
statistical comparison with the 10 patients, much fewer than in
the Symplicity trial, and who were not followed as long
following the ablation. Thus, at present, any comparison in
outcomes and complications drawn from experiences with 2
different catheters would be, at best, totally inappropriate.
Finally, any concluding comment, such as that made by
Dr. Mehmet Oz, host of the nationally syndicated television
talk show, reflects premature excitement (21). Oz commented
that “there is reason for a happier New Year” (if one has
hypertension) and that promise from the “large” Symplicity
trial’s results in 2012 are awaited. However, he did not caution
that if one has hypertension, it must be resistant to antihyper-
tensive treatment consisting of 3 medications (including a
diuretic) to be considered for the procedure. Consequently, the
mass extrapolation to all patients with hypertension for the
promise of this very specialized procedure does not seem
appropriate at present. Clearly, for the larger group of
patients with hypertension, they should not be considered
for renal arterial ablation therapy. They should be seeking
care from their physicians and, if the patients’ blood
pressure is established as abnormally elevated, they should
be treated and followed closely so that their blood pressures
remain well controlled by conventional nondrug and drug
therapy.
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